GlassScriptPhysician profile
Eren Taydas
NPI 1902164742
$8,942.47
in general payments reported to CMS, 2019-2025
31 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $273 · 2021: $1,392 · 2022: $1,550 · 2023: $1,409 · 2024: $2,697 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,273 · Education: $57.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,272.50 |
| Education | $57.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,708.90 | 2019-2025 | Linzess, Creon, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,073.23 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $1,022.21 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $890.78 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $888.46 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $405.80 | 2023-2025 | |
| Gilead Sciences, INC. | $404.45 | 2021-2025 | |
| Ardelyx, INC. | $328.95 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $253.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $238.23 | 2021-2024 | Talicia |
| Intercept Pharmaceuticals, INC. | $205.63 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $201.38 | 2019-2024 | Dificid, Zinplava |
| Phathom Pharmaceuticals, INC. | $200.85 | 2024-2025 | Voquezna |
| Genzyme Corporation | $167.25 | 2024-2025 | |
| Lilly USA, LLC | $159.65 | 2024-2025 | Omvoh |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $150.32 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $125.35 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $99.05 | 2022-2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $85.75 | 2021-2022 | |
| Braintree Laboratories, INC. | $62.77 | 2019-2021 | |
| Celltrion USA INC. | $56.71 | 2024 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $32.16 | 2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $29.36 | 2019-2020 | |
| Palette Life Sciences, INC. | $25.69 | 2022 | |
| Laborie Medical Technologies Corp. | $25.43 | 2023 | |
| Fresenius Kabi USA, LLC | $22.75 | 2023 | |
| Alnylam Pharmaceuticals INC. | $17.70 | 2023 | Givlaari |
| Concordia Pharmaceuticals INC. | $17.41 | 2019 | |
| Cook Medical LLC | $16.24 | 2021 | |
| Allergan, INC. | $15.40 | 2019 | |
| Boston Scientific Corporation | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eren Taydas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.